Stock Analysis

3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 26.5%

TSE:2127
Source: Shutterstock

In recent weeks, global markets have been influenced by rising U.S. Treasury yields and subdued economic growth, leading to a mixed performance across major indices. As investors navigate these uncertain conditions, identifying stocks that are trading below their intrinsic value can offer potential opportunities for long-term gains. In such an environment, a good stock is often characterized by strong fundamentals and resilience in the face of broader market fluctuations.

Top 10 Undervalued Stocks Based On Cash Flows

NameCurrent PriceFair Value (Est)Discount (Est)
Provident Financial Services (NYSE:PFS)US$19.03US$37.9249.8%
Western Alliance Bancorporation (NYSE:WAL)US$84.27US$168.2449.9%
California Resources (NYSE:CRC)US$52.32US$104.3549.9%
Beyout Investment Group Holding Company - K.S.C. (Holding) (KWSE:BEYOUT)KWD0.395KWD0.7949.9%
Acerinox (BME:ACX)€8.52€16.9849.8%
Semiconductor Manufacturing International (SEHK:981)HK$27.05HK$53.7849.7%
SBI Sumishin Net Bank (TSE:7163)¥2706.00¥5411.1850%
ChromaDex (NasdaqCM:CDXC)US$3.58US$7.1549.9%
Energy One (ASX:EOL)A$5.53A$11.0650%
Fine Foods & Pharmaceuticals N.T.M (BIT:FF)€8.36€16.7049.9%

Click here to see the full list of 965 stocks from our Undervalued Stocks Based On Cash Flows screener.

Underneath we present a selection of stocks filtered out by our screen.

Beijing Huafeng Test & Control TechnologyLtd (SHSE:688200)

Overview: Beijing Huafeng Test & Control Technology Co., Ltd. operates in the field of test and control technology, with a market cap of approximately CN¥15.56 billion.

Operations: The company's revenue segments are not specified in the provided text.

Estimated Discount To Fair Value: 13.3%

Beijing Huafeng Test & Control Technology Ltd. reported sales of CNY 621.2 million for the first nine months of 2024, up from CNY 518.73 million a year ago, with net income rising to CNY 213.09 million. Despite its low forecasted return on equity and recent share price volatility, the stock trades at CN¥119.88, below its estimated fair value of CN¥138.33, with significant expected earnings growth of 35% annually over three years.

SHSE:688200 Discounted Cash Flow as at Oct 2024
SHSE:688200 Discounted Cash Flow as at Oct 2024

Winner Medical (SZSE:300888)

Overview: Winner Medical Co., Ltd. focuses on the R&D, manufacturing, and marketing of cotton-based medical dressings and disposables in China, with a market cap of CN¥18.38 billion.

Operations: The company generates revenue from cotton-based medical dressings, medical disposables, and consumer products in China.

Estimated Discount To Fair Value: 26.5%

Winner Medical's recent earnings show a decline in net income to CNY 552.97 million for the first nine months of 2024, down from CNY 2.15 billion a year ago, though sales increased slightly to CNY 6.07 billion. The stock trades at CN¥31.19, below its estimated fair value of CN¥42.45, indicating undervaluation based on cash flows despite low forecasted return on equity and unsustainable dividend coverage from earnings or cash flows.

SZSE:300888 Discounted Cash Flow as at Oct 2024
SZSE:300888 Discounted Cash Flow as at Oct 2024

Nihon M&A Center Holdings (TSE:2127)

Overview: Nihon M&A Center Holdings Inc. offers mergers and acquisitions-related services both in Japan and internationally, with a market cap of ¥188.33 billion.

Operations: The company generates revenue primarily through its M&A Consulting Business, which accounted for ¥43.53 billion.

Estimated Discount To Fair Value: 22.5%

Nihon M&A Center Holdings is trading at ¥667.5, significantly below its estimated fair value of ¥860.79, highlighting potential undervaluation based on cash flows. The company's revenue is expected to grow by 9.5% annually, outpacing the Japanese market's growth rate of 4.2%. Although earnings growth isn't significant, it's projected at 9.8%, surpassing the market average of 8.8%. The stock also offers a reliable dividend yield of 3.45%.

TSE:2127 Discounted Cash Flow as at Oct 2024
TSE:2127 Discounted Cash Flow as at Oct 2024

Summing It All Up

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Nihon M&A Center Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com